Management considerations for a heterozygous protein C deficient patient undergoing open heart surgery with cardiopulmonary bypass.

The protein C system is an important antithrombotic pathway that regulates the coagulation system by inactivating procoagulant factors Va and VIIIa and enhancing clot lysis by inhibiting the activity of plasminogen activator inhibitor. Protein C deficiency, therefore, is a hypercoaguable state characterized by increased risk of thromboembolic events such as stroke, pulmonary embolism, and venous thrombosis. Extra caution would be warranted in patients with protein C deficiency who undergo cardiopulmonary bypass and are naturally predisposed to hypercoaguability. To our knowledge, however, the management considerations of a patient with protein C deficiency undergoing cardiopulmonary bypass have not been published. This case report presents a pediatric patient with heterozygous protein C deficiency and a prior history of venous thrombosis after open heart surgery who underwent repeat open heart surgery with cardiopulmonary bypass. Initiation of anticoagulation therapy upon admission to reduce procoagulant levels, the use of plasma replacement therapy to increase protein C levels prior to cardiopulmonary bypass, and the careful reinstatement of anticoagulation therapy once postoperative bleeding is controlled, are preliminary suggestions to decrease the risk of thrombotic events in this unusual patient population.

[1]  A. Schafer Hypercoagulable states: molecular genetics to clinical practice , 1994, The Lancet.

[2]  G. Hempelmann,et al.  Thrombomodulin in pediatric cardiac surgery. , 1994, The Annals of thoracic surgery.

[3]  G. Hempelmann,et al.  Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[4]  R. Minns,et al.  Protein C and S Deficiency Causing Childhood Stroke , 1993, Scottish medical journal.

[5]  R. Marlar,et al.  Protein C survival during replacement therapy in homozygous protein C deficiency , 1992, American journal of hematology.

[6]  C. Esmon The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  P. Feindt,et al.  The Role of Protein C as an Inhibitor of Blood Clotting During Extracorporeal Circulation , 1991, The Thoracic and cardiovascular surgeon.

[8]  J. Lazarchick,et al.  Protein C deficiency as a cause of pulmonary embolism in the perioperative period. , 1991, Anesthesiology.

[9]  E. Sheffield,et al.  Protein C deficiency associated with massive cerebral thrombosis following open heart surgery. , 1990, The Journal of cardiovascular surgery.

[10]  P. Petrini,et al.  Homozygous protein C deficiency in two siblings. , 1990, Pediatric hematology and oncology.

[11]  J. Griffin,et al.  Aprotinin (trasylol) is a competitive inhibitor of activated protein C. , 1989, Thrombosis research.

[12]  I. Yada,et al.  The role of the protein C-thrombomodulin system in physiologic anticoagulation during cardiopulmonary bypass. , 1989, ASAIO transactions.

[13]  T. Emerson Pharmacology of Aprotinin and Efficacy During Cardiopulmonary Bypass , 1989 .

[14]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[15]  P. Knöbl,et al.  The protein C system in patients undergoing cardiopulmonary bypass. , 1987, The Journal of thoracic and cardiovascular surgery.

[16]  I. Yada,et al.  Physiologic role of enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery. , 1987, ASAIO transactions.

[17]  P. Comp,et al.  The regulation of hemostasis: the protein C system. , 1986, The New England journal of medicine.

[18]  H. Soloway,et al.  Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient. Implications relative to the etiology of heparin rebound. , 1980, American journal of clinical pathology.

[19]  C. J. Lambert,et al.  The Treatment of Postperfusion Bleeding Using ε-Aminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate , 1979 .